Change over period
From:
To:
Zoom:
- 1Y
- 3Y
- 5Y
- 10Y
- 15Y
- 20Y
- Max
Harpoon Therapeutics Inc
NASDAQ HARP
Data sourced from
and
and
Harpoon Therapeutics Inc Dividend Coverage Ratio 5 year CAGR for the Trailing 12 Months (TTM) ending September 20, 2024
Harpoon Therapeutics Inc Dividend Coverage Ratio 5 year CAGR is NA for the Trailing 12 Months (TTM) ending September 20, 2024. The dividend coverage ratio measures a company's ability to cover its dividend payments with its net income. It is calculated by dividing net income by dividends paid. This ratio indicates the proportion of net income that is allocated to paying dividends. A ratio greater than 1 suggests sufficient income to cover dividend payments, while a ratio less than 1 indicates a potential shortfall. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.
Don’t Miss A Beat
Looking to stay ahead of the competition and stay informed? Receive your daily dose of market news, trends, and analysis to kickstart your day and stay up-to-date.
NASDAQ: HARP
| CEO | Ms. Julie M. Eastland M.B.A. |
| IPO Date | Feb. 8, 2019 |
| Location | United States |
| Headquarters | 131 Oyster Point Boulevard, South San Francisco, CA, United States, 94080 |
| Employees | 53 |
| Sector | Healthcare |
| Industry | Biotechnology |
Description
Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. The company develops tri-specific T cell activating construct (TriTAC) product candidate, including HPN328, which is in Phase I/II clinical trials for the treatment of small cell lung cancer and other Delta-like canonical Notch ligand 3-expressing tumors; and HPN217 that is in Phase I clinical trials for the treatment of multiple myeloma. Its preclinical stage product is HPN601 for the treatment of multiple solid tumor indications. It has a discovery collaboration and license agreement with AbbVie Biotechnology Ltd. to develop and commercialize products that incorporate its proprietary TriTAC platform technology together with soluble T cell receptors. The company was incorporated in 2015 and is headquartered in South San Francisco, California. As of March 11, 2024, Harpoon Therapeutics, Inc. operates as a subsidiary of Merck Sharp & Dohme LLC.
Key trends
Similar companies
Stoke Therapeutics Inc
NA
NA
StockViz Staff
September 20, 2024
Any question? Send us an email